VEGFR2/Flk-1/KDR human
SIGMA/SRP6406 - recombinant, expressed in HEK 293 cells, ≥95% (SDS-PAGE)
Synonym: CD309; VEGFR; kinase insert domain receptor
Product Type: Chemical
VEGF Pathway Research areas: Angiogenesis, Metastasis, Hypoxia, Osteogenesis, Developmental biology Disease areas: Cancer, Osteoporosis, Ischemic stroke, Inflammation, Rheumatoid Arthritis, Diabetes See also: SRP3182; SRP4363; V5765; SRP4634; SRP4364; SRP4365, SRP3184
Immunoblotting VEGFR2/Flk-1/KDR Cat. No. SRP6406, SDS PAGE of human recombinant VEGFR2/Flk-1/KDR.
| assay | ≥95% (SDS-PAGE) |
| biological source | human |
| form | lyophilized |
| impurities | <1 EU/μg endotoxin (LAL test) |
| mol wt | calculated mol wt 84.1 kDa |
| observed mol wt 100-110 kDa by SDS-PAGE (DTT-reduced. Protein migrates due to glycosylation.) | |
| packaging | pkg of 100 μg |
| pkg of 20 μg | |
| recombinant | expressed in HEK 293 cells |
| shipped in | wet ice |
| storage temp. | −20°C |
| tag | 6-His tagged (C-terminus) |
| UniProt accession no. | P35968   |
| General description: | Kinase insert domain receptor (KDR) also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF. The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi′s sarcoma lesions. |
| Physical form: | Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization. |
| Reconstitution: | Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 μg/mL. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (SDS-PAGE) |
| Storage Temp. | −20°C |
| UNSPSC | 12352200 |